Vyleesi Compassionate Use and Expanded Access: What Women Need to Know in 2026

What Vyleesi Is and Why Access Matters

Vyleesi is the only FDA-approved on-demand injectable treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by persistently low sexual desire that causes marked distress, and it affects an estimated 10 percent of premenopausal women in the United States. That is not a small number. Despite its FDA approval, Vyleesi remains difficult to access because commercial insurance coverage is inconsistent, list prices are high, and many women are not aware that cost-reduction pathways exist.

Bremelanotide works differently from flibanserin (Addyi), the other FDA-approved HSDD medication. Rather than requiring daily dosing, you inject Vyleesi subcutaneously in the abdomen or thigh roughly 45 minutes before sexual activity, up to one time in 24 hours and no more than once per week on average as outlined in the prescribing information. Because it is used on demand, a single kit lasts longer for some women than it would for others, which affects how you calculate your real monthly cost.

Understanding access pathways is genuinely clinical, not just financial. If cost prevents you from filling your prescription, the drug provides no benefit. This article covers every legitimate access pathway available as of early 2026, including what "compassionate use" and "expanded access" actually mean in the context of a drug that is already FDA-approved.

What Compassionate Use and Expanded Access Actually Mean

The FDA Definition

"Compassionate use" is an informal term for what the FDA officially calls expanded access. Expanded access allows patients with serious or life-threatening conditions to receive investigational drugs outside of a clinical trial. The key word is investigational. These programs are designed for drugs that have not yet received FDA approval, or for approved drugs being studied for new indications.

Why This Matters for Bremelanotide Specifically

Bremelanotide received full FDA approval in June 2019. Because it is already approved, a traditional expanded access program for HSDD in premenopausal women does not exist in the way one might for an experimental cancer drug. Any woman with a valid prescription can theoretically obtain Vyleesi through a licensed pharmacy. The real barrier is cost and insurance, not regulatory access.

There is one exception worth knowing: if a physician wants to use bremelanotide for an indication not covered by the current label, such as HSDD in postmenopausal women or HSDD related to a medical condition not studied in the approval trials, they may apply for an individual patient Investigational New Drug (IND) application with the FDA. This is a physician-sponsored pathway, not a manufacturer program, and it requires significant paperwork. It is rare in routine clinical practice.

When to Ask Your Clinician About an IND

The following framework can help you and your clinician decide whether an individual IND conversation makes sense for your situation:

• You are postmenopausal and your clinician believes bremelanotide may address your HSDD after standard therapies have failed.
• You have a medical or surgical condition (such as bilateral oophorectomy or premature ovarian insufficiency) that was excluded from the RECONNECT trials.
• You are being managed at an academic medical center where IND infrastructure already exists.
• Your clinician has documented prior treatment failures with both flibanserin and non-pharmacological approaches.

For most women seeking Vyleesi in 2026, the practical path is not an IND. It is one of the cost-reduction options described below.

The Evidence Base: What the Approval Trials Found

The RECONNECT trials (two phase 3, randomized, double-blind, placebo-controlled studies published in Obstetrics and Gynecology in 2019) remain the primary evidence base for bremelanotide. Across both trials, women receiving bremelanotide 1.75 mg showed a statistically significant increase in the number of satisfying sexual events compared with placebo. Specifically, bremelanotide-treated women reported a mean decrease of 1.2 points on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) compared with 0.8 points for placebo, a difference that reached statistical significance but that is clinically modest.

The trials enrolled premenopausal women with generalized, acquired HSDD. That is a specific population. Women with situational HSDD, women with primary HSDD (low desire lifelong rather than a change from a prior baseline), and women over the natural menopause transition were not the target population. This matters for access discussions because coverage criteria often mirror the trial population.

Nausea occurred in approximately 40 percent of bremelanotide-treated women in the trials, compared with around 1 percent of placebo recipients. Flushing affected roughly 20 percent. Transient increases in blood pressure averaging 6 mmHg systolic occurred within 12 hours of dosing. These side-effect rates are clinically meaningful when counseling a patient on whether to start the drug.

Sex-Specific Physiology: How Hormonal Status Affects Bremelanotide

Bremelanotide is a melanocortin receptor agonist. It binds MC1R and MC4R receptors in the central nervous system to modulate sexual desire pathways. Estrogen interacts with melanocortin signaling, which is one reason why sexual desire is not a fixed biological constant for women across the lifespan.

Reproductive Years

In women of reproductive age with regular cycles, desire naturally fluctuates around ovulation (typically higher in the periovulatory phase when estradiol peaks) and tends to be lower in the late luteal phase. The RECONNECT trials did not stratify outcomes by cycle phase, so it is not known whether timing Vyleesi use within the menstrual cycle affects response. This is a genuine evidence gap.

Perimenopause

Perimenopause brings erratic estrogen fluctuations, rising FSH, and for many women a noticeable decline in sexual desire that overlaps with HSDD criteria. Bremelanotide is approved for premenopausal women. Women who are perimenopausal but still menstruating may technically fall within the label, though clinical trial data in this sub-group is thin. The Menopause Society (NAMS) 2022 position statement on sexual health does not endorse bremelanotide for perimenopausal or postmenopausal women as a first-line agent, noting insufficient data in those populations.

Postmenopause

Vyleesi is not FDA-approved for postmenopausal women. The prescribing information explicitly states this limitation. Postmenopausal women with HSDD have fewer pharmacological options. Ospemifene addresses genitourinary syndrome of menopause but not central desire. Systemic hormone therapy may improve desire as a secondary benefit in some women. For postmenopausal women who have exhausted these options, a physician-sponsored IND as described above is the regulatory mechanism, though it is rarely pursued outside academic centers.

Pregnancy, Lactation, and Contraception: Required Reading Before You Fill This Prescription

Vyleesi is contraindicated in pregnancy. This is a firm contraindication, not a precaution.

Animal and Human Pregnancy Data

In animal reproduction studies, bremelanotide administered during organogenesis at exposures approximately 3 times the human exposure at the recommended dose resulted in fetal harm including increased post-implantation loss and reduced fetal weight. Human pregnancy data are limited because the drug was not studied in pregnant women. Given the mechanism (central melanocortin agonism) and the animal data, use during pregnancy should be avoided.

Contraception Requirement

Because Vyleesi is used on demand rather than daily, you may not always be thinking about contraception at the moment of use. The FDA prescribing information advises women to use effective contraception during treatment. If you are trying to conceive, this drug is not appropriate for you at that time. Discuss timing carefully with your clinician if you are in a phase of life where pregnancy is possible and desired within the next year.

If you become pregnant while using bremelanotide, contact your clinician immediately and report the exposure to the Palatin Technologies pregnancy registry as directed in the labeling.

Lactation

There are no human data on bremelanotide transfer into breast milk. Animal data show that bremelanotide is present in rat milk. Because of the potential for adverse effects in a breastfed infant and because the drug's half-life is approximately 2.7 hours, a reasonable clinical approach is to pump and discard milk for at least 24 hours after each dose. The prescribing information recommends avoiding bremelanotide during breastfeeding entirely. If you are postpartum and breastfeeding and experiencing low desire, discuss the distinction between postpartum HSDD and normal postpartum libido changes with your clinician before requesting this medication.

Real Access Pathways in 2026: A Practical Guide

Manufacturer Savings Card (AMAG/Palatin)

The most widely used access tool for commercially insured patients is the manufacturer savings card. As of 2026, eligible patients with commercial insurance may pay as little as $0 per prescription. The card does not apply to federally funded insurance, meaning Medicare, Medicaid, TRICARE, or any other government plan makes you ineligible. Eligibility and card terms change; verify current details directly at the manufacturer site or through your pharmacist.

Insurance Coverage and Prior Authorization

Commercial insurance coverage for Vyleesi varies widely by plan. Many plans require prior authorization that documents:

• A diagnosis of HSDD confirmed by a licensed clinician
• Absence of a better-explained cause (such as untreated depression, relationship factors, or a medication side effect)
• Failure or contraindication to non-pharmacological first-line approaches
• Documentation that flibanserin was considered or tried

Your clinician's office typically handles prior authorization paperwork, but you can accelerate the process by providing a complete medication history and any prior mental health or sexual health evaluations at your initial visit.

HSA and FSA Accounts

Vyleesi purchased with a valid prescription is an eligible expense under both Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). The IRS defines qualified medical expenses as amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. A prescription drug for an FDA-approved indication meets this definition. Using pre-tax dollars through an HSA or FSA effectively reduces your real out-of-pocket cost by your marginal tax rate, which for many women is 22 to 24 percent.

If your plan's savings card brings your cost to $0, there is nothing to pay with HSA/FSA funds. But for women paying list price or a high-deductible copay, stacking an HSA/FSA payment on top is the most straightforward cost-reduction tool available without a third party.

Compounding Pharmacies and Generic Bremelanotide

Bremelanotide is not available as an FDA-approved generic as of early 2026. However, some compounding pharmacies prepare bremelanotide peptide injections at significantly lower price points, often $100 to $250 per vial depending on concentration and quantity. This is the same active peptide sequence, but compounded drugs are not FDA-reviewed for the specific preparation and carry different quality assurance standards than the branded product.

Compounded bremelanotide is legal when prepared by a state-licensed 503A or 503B pharmacy, but it is not interchangeable with Vyleesi from a regulatory standpoint. If you pursue this route, ask your pharmacy for documentation of USP <797> compliance (sterile compounding standards) and request a certificate of analysis. Telehealth platforms that specialize in sexual health and peptide therapies have made this route more accessible in recent years.

The FDA has not placed bremelanotide on its list of drugs withdrawn from the market for safety reasons, which means compounding is not categorically prohibited. The practical risk is batch-to-batch consistency, not legality.

Telehealth Platforms

Several telehealth companies now prescribe and coordinate delivery of either branded Vyleesi or compounded bremelanotide. Consultation fees vary from $0 to $150 per visit depending on the platform. Some platforms bundle the prescription with the compounded medication at a flat monthly or per-use price. When evaluating a telehealth platform, confirm that:

• The prescribing clinician is licensed in your state
• The compounding pharmacy holds a valid state pharmacy license and PCAB or equivalent accreditation
• The platform has a clear mechanism for follow-up if you experience adverse effects

Patient Assistance Programs

Palatin Technologies is a smaller biopharmaceutical company and has not historically maintained a strong free drug program comparable to large pharmaceutical manufacturers. If you are uninsured or underinsured and the savings card does not apply to your situation, contact Palatin directly and ask whether any patient assistance is available. Programs change, and this is an area where persistence in calling the manufacturer pays off.

NeedyMeds and RxAssist are two national databases that aggregate patient assistance programs; search both for current bremelanotide listings, though as of early 2026 listings in these databases for this specific drug are limited.

Who This Drug Is Right For and Who Should Pause

Women Who May Be Good Candidates

• Premenopausal women with acquired, generalized HSDD causing significant personal distress
• Women who have addressed potential contributing factors (depression, relationship conflict, medication side effects) and still experience low desire
• Women who prefer on-demand dosing over daily medication
• Women for whom flibanserin's daily dosing schedule, alcohol interaction, or CNS side effects are prohibitive

Women Who Should Pause or Avoid

• Women who are pregnant or actively trying to conceive
• Women who are breastfeeding (unless willing to pump-and-discard for 24 hours and have discussed with clinician)
• Women with uncontrolled hypertension or known cardiovascular disease (transient blood pressure increase of approximately 6 mmHg systolic occurs with each dose)
• Women with a history of melanoma or dysplastic nevi (bremelanotide stimulates MC1R, which affects melanocyte signaling; this is a labeled precaution, not a contraindication, but warrants dermatology input)
• Postmenopausal women seeking an approved on-label option (evidence is insufficient for this group)
• Women with situational rather than generalized HSDD (the drug was not studied in situational presentations)

Life-Stage Framing Summary

| Life Stage | Approved? | Key Consideration | |---|---|---| | Reproductive years (regular cycles) | Yes | Effective contraception required | | Trying to conceive | No | Contraindicated | | Pregnancy | No | Contraindicated; animal harm data | | Postpartum / breastfeeding | Avoid | Limited data; pump-and-discard if used | | Perimenopause (still menstruating) | Technically within label | Thin sub-group data | | Postmenopause | Off-label only | No approved indication; consider IND pathway if no alternatives |

Navigating the Prior Authorization Process

Prior authorization denials are common on the first attempt. Here is a practical sequence:

1. Ask your clinician to use the specific HSDD ICD-10 code (F52.0, inhibited sexual desire) in the authorization request.
2. Request that the authorization letter explicitly reference the RECONNECT trial data as the evidence basis for the prescription.
3. If denied, file a formal appeal within your plan's required window (typically 30 to 60 days). Include a letter of medical necessity from your clinician.
4. If the internal appeal fails, request an independent external review, which is required by law in most states for denials of FDA-approved medications.
5. ACOG Committee Opinion 779 supports clinical evaluation and treatment of female sexual dysfunction, which can be referenced in appeal letters.

A 2021 analysis in JAMA Internal Medicine found that a majority of prior authorization appeals that went to external review were decided in the patient's favor. Filing the appeal is worth doing.

Evidence Gaps and What Is Extrapolated

Be candid with yourself and your clinician about what is and is not known.

Women of color were underrepresented in the RECONNECT trials. The studies enrolled predominantly white women, which means the treatment effect estimates may not generalize equally across racial and ethnic groups. This is a direct limitation of the trial design that the FDA acknowledged in its medical review documents.

Long-term safety data beyond 52 weeks are limited. The label reflects this. Skin hyperpigmentation, particularly of the face, gums, and breasts, has been reported and may be permanent with extended use. This is a melanocortin-pathway effect and is more likely with prolonged or frequent use.

The drug has not been studied head-to-head against flibanserin. Clinicians make a choice between these two agents based on patient preference, dosing schedule, and side-effect profile, not comparative efficacy data.

A Note on Telehealth Prescribing and Your Rights

Some states restrict telehealth prescribing of Schedule IV controlled substances, but bremelanotide is not a controlled substance, which simplifies telehealth prescribing considerably. A clinician licensed in your state can prescribe Vyleesi after a telehealth consultation in virtually all states as of 2026. You do not need to see a specialist in person to obtain this prescription, though a gynecologist or women's-health NP with experience in sexual medicine will typically conduct a more thorough HSDD evaluation than a general-purpose telehealth platform.

"The goal of HSDD treatment is meaningful improvement in the patient's own experience of desire and distress, not achieving a particular score on a scale," said a WomanRx editorial board clinician. "Access barriers that prevent women from even trying an FDA-approved medication are a clinical problem, not just an administrative inconvenience."